Search

Displaying results 2761 - 2770 of 4234 in total
  1. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    [A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised … [A262965] Previously, the first line treatment for molluscum contagiosum was surgical excision, although it poses challenges such as repeated doctor visits, post-surgical scarring and skin discoloration

  2. Drug

    mRNA-1010

    go.drugbank.com/drugs/DB22484
    Approved

    [L64058,L64060] It is administered as a single intramuscular dose. … the hemagglutinin (HA) glycoprotein of one influenza strain recommended for the season; after intramuscular injection, host cells translate the mRNA into HA proteins that the immune system recognizes as

  3. Drug

    Cythioate

    go.drugbank.com/drugs/DB11392
    ExperimentalVet approved

    Cythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic. It is mainly used in veterinary as a treatment for fleas.

  4. Drug

    Water

    go.drugbank.com/drugs/DB09145
    ApprovedInvestigational

    As a chemical compound, a water molecule contains one oxygen and two hydrogen atoms that are connected by covalent bonds.

  5. Drug

    Diphemanil

    go.drugbank.com/drugs/DB13720
    ApprovedVet approvedWithdrawn

  6. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued.

  7. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    They are a family of fatty acid molecules that act as precursors to potent lipid mediator signalling molecules with either pro-inflammatory and anti-inflammatory effects. … Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory.

  8. Drug

    Reldesemtiv

    go.drugbank.com/drugs/DB15256
    Investigational

    Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).

  9. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients

    Synonyms: Immunoglobulin g1, anti-(human interleukin 5) (human-mus musculus monoclonal gsk3511294 .gamma.1-chain), disulfide with human-mus musculus monoclonal gsk3511294 .kappa.-chain, dimer
  10. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression